Fig. 6: Analysis of in vivo therapeutic response of trastuzumab in orthotropic breast tumors.
From: Hotspot mutations in HER2 interfaces destabilize structure, causing breast cancer treatment failure
A Representative bioluminescence images of H2-WT tumor-bearing mice in untreated and treated arms. B Graph representing quantitative photonic signal (average radiance) from tumor site of the mice over time. C Representative bioluminescence images of S310F tumor-bearing mice in untreated and treated arms. D Graph representing quantitative photonic signal (average radiance) from tumor site of the mice over time. E Representative bioluminescence images of P523S tumor-bearing mice in untreated and treated arms. F Graph representing quantitative photonic signal (average radiance) from tumor site of the mice over time. Error bars represent ± standard deviation for five mice/group. G Western blots showing levels of p-HER2, pan-HER2, p-HER3, and pan-HER3 measured from harvested H2-WT, S310F, and P523S tumor samples treated or untreated with trastuzumab. H Graph showing measured average radiance values from metastatic nodules in the harvested critical organs like lungs, liver, bone, and brain at the end point of the above three mice cohorts.
